2007ESH/ESC Guidelines for the management of hypertension, from theory to practice: Global cardiovascular risk concept

Journal of Hypertension

Volumn 27, Issue SUPPL. 3, 2009, Pages

  Volpe, Massimo ^a   Toccib, Giuliano ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Cardiovascular mortality; Cardiovascular prevention; Cardiovascular risk; Hypercholesterolemia; Hypertension; Organ damage

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; FAMILY HISTORY; HUMAN; HYPERTENSION; IMMOBILIZATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; EUROPE; RISK FACTOR;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; EUROPE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 69149095761     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000356766.86388.e5     Document Type: Review

References (78)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
3. Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
5. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342:1-8.
6. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242:2562-2571.
7. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1545.
8. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1st March 2003. J Hypertens 2003; 21:1055-1076.
9. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin converting enzyme inhibitors and calcium channel blockers for coronary artery disease and stroke prevention. Hypertension 2005; 46:386-392.
10. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial (MRFIT) research group. Arch Intern Med 1992; 152:56-64.
11. Martiniuk AL, Lee CM, Lawes CM, Ueshima H, Suh I, Lam TH, et al., for the Asia-Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007; 25:73-79.
12. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952. (Pubitemid 39208455)
13. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289:2560-2571.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
15. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2):3S-10S.
16. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
17. Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002; 15:917-923.
18. Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, et al. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens 2004; 17:1068-1074.
19. Volpe M, Tocci G, Pagannone E. Less mega-trials and more clinically oriented studies in hypertension research? The case of blocking renin-angiotensin-aldosterone system. J Am Soc Nephrol 2006; 17 (4 Suppl 2):S36-S43.
20. Giles TD, Berk BC, Black HR, Cohn JN, Kostis JB, Izzo JL Jr, Weber MA. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005; 7:505-512.
21. Sesti G, Volpe M, Cosentino F, Crepaldi G, Del Prato S, Mancia G, et al. Metabolicsyndrome:diagnosisandclinicalmanagement,anofficialdocument of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13:185-198.
22. Cuspidi C, Mancia G, Ambrosioni E, Pessina A, Trimarco B, Banchetti A, on behalf of the APROS Investigators. Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the Assessment Prognostic Risk Observational Survey (APROS). J Human Hypertens 2004; 18:891-896.
23. Böhm M, Thoenes M, Danchin N, Bramlage P, La Puerta P, Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25:2317-2324.
24. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
25. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393. (Pubitemid 36159355)
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLA). JAMA 2002; 288:2981-2997.
27. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
28. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, et al., HOPE/ HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112:1339-1346.
29. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
30. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. J Hum Hypertens 2008; 22:154-157.
31. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A Statement for Healthcare Professional from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34:1348-1359. (Pubitemid 29500569)
32. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al., for the Coordinating Committee of the National Cholesterol Education Program (NCEP). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
33. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al., for the British Hypertension Society (BHS) Guidelines. Guidelines of management of hypertension: report of the fourth working party on British Hypertension Society-BHS IV. J Hum Hypertens 2004; 18:139-185.
34. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al., European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS).. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2):S1-S113.
35. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al., Task Forceon Diabetes and Cardiovascular Diseases of the European Society ofCardiology (ESC); European Association for the StudyofDiabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28:88-136.
36. Tocci G, Valenti V, Sciarretta S, Volpe M. Multivariate risk assessment and risk score cards in hypertension. Vasc Health Risk Manage 2007; 3:313-320.
37. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139:272-278.
38. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25:484-491.
39. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791-798.
40. Tunstal-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ 1991; 303:744-747.
41. Panico S, Palmieri L, Vanuzzo D, Ferrario M, Giampaoli S, Gruppo di Ricerca del Progetto CUORE-Studi Longitudinali. Risk of major first cardiovascular event among Italian women: results of the CUORE Project. Ital Heart J 2004; 5 (Suppl. 8):59S-63S.
42. Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31:1253-1262. (Pubitemid 36204492)
43. SheridanS, PignoneM,Mulrow C. Framinghan-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18:1039-1052.
44. MenottiA, Puddu PE, Lanti M.Comparison ofthe Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21:365-370.
45. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, et al. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol 2007; 22:747-754.
46. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18:1039-1052.
47. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al., for the European Systematic COronary Risk Evaluation (SCORE) project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
48. Volpe M, Rosei EA, Ambrosioni E, Leonetti G, Trimarco B, Mancia G. Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. J Hypertens 2007; 25:2390-2397.
49. World Health Organization (WHO)/International Society of Hypertension (ISH). 1999 Guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
50. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC VI Report. Arch Intern Med 1997; 157:2413-2445.
51. Wolf-MaierK, Cooper RS, BanegasJR, GiampaoliS,Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363-2369.
52. Boersma E, Keil U, De Bacquer D, De Backer G, Pyorala K, Poldermans D, et al., for the EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21:1831-1840.
53. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1498.
54. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317:167-171.
55. El Fakiri F, Bruijnzeels MA, Hoes AW. Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk. Heart 2006; 92:741-745.
56. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and cosAts of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361:717-725; [Erratum in Lancet 2005; 366:204.].
57. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11:1-160.
58. Volpe M, Erhardt LR, Williams B. Cardiovascular risk management in clinical practice: time to change. High Blood Press Cardiovasc Prev 2008; 15:9-16.
59. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121:1244-1263.
60. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
61. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-1046. (Pubitemid 39319000)
62. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969-975.
63. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson S, et al., Italian Association of Hospital Cardiologists; Italian Society of Cardiology; Italian Federation of Cardiology; Italian Society of Clinical Chemistry and Molecular Biology; Italian Society of Laboratory Medicine; Italian Society of Emergency Medicine. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005; 6:430-446.
64. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
65. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
66. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diabet Vasc Dis Res 2007; 4:143-150.
67. Brown ER, Kronmal RA, Bluemke DA, Guerci AD, Carr JJ, Goldin J, Detrano R. Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. Radiology 2008; Epub ahead of print.
68. Sattar N. The metabolic syndrome: should current criteria influence clinical practice? Curr Opin Lipidol 2006; 17:404-411.
69. Haffner SM, Ruilope L, Dahlöf B, Abadie E, Kupfer S, Zannad F. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol 2006; 47:469-475.
70. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998. (Pubitemid 39336683)
71. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822. (Pubitemid 38622521)
72. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
73. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
74. Dahlof B, Devereux RB, Kjeldsen SE, Julius H Beevers G, Faire U, et al., for The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
75. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al., for the MOrbidity and Mortality after Stroke, Eprosartan compared with nitrendipine for Secondary prevention (MOSES) Study Group. Principal results of a prospective randomized controlled study. Stroke 2005; 36:1218-1226.
76. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al., Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369:1431-1439.
77. Volpe M, Tocci G. Antihypertensive therapy and cerebrovascular protection. Curr Opin Nephrol Hypertens 2006; 15:498-504.
78. Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Pressure 2005; 14:196-209.